Ethyl 3-guanidino-4-methylbenzoate nitrate | CAS:641569-96-2

We serve Ethyl 3-guanidino-4-methylbenzoate nitrate CAS:641569-96-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Ethyl 3-guanidino-4-methylbenzoate nitrate

Chemical Name:Ethyl 3-guanidino-4-methylbenzoate nitrate
CAS.NO:641569-96-2
Synonyms:3-[(Aminoiminomethyl)amino]-4-methylbenzoic acid ethyl ester mononitrate
Molecular Formula:C11H16N4O5
Molecular Weight:284.26900
 
Physical and Chemical Properties:
Melting point:199ºC
 
Specification:
Appearance:White crystalline powder
Purity:≥99.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Nilotinib
 
Note:The product under valid patents will not be offered to the countries covered by patents.



Contact us for information like Ethyl 3-guanidino-4-methylbenzoate nitrate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-[(Aminoiminomethyl)amino]-4-methylbenzoic acid ethyl ester mononitrate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Ethyl 3-guanidino-4-methylbenzoate nitrate Use and application,Ethyl 3-guanidino-4-methylbenzoate nitrate technical grade,usp/ep/jp grade.


Related News: It does not require a production license for the drug substance, and can be produced in an ordinary chemical plant. As long as it reaches a certain level, it can be used for the synthesis of the drug substance.4-Bromobenzyl bromide manufacturer Therefore, the R & D capabilities and registration capabilities of API companies have become the core factors of competition.4-nitrobenzyl bromide supplier The novel coronavirus has resulted in thousands of confirmed human infections in more than 20 countries, with more than 99 percent of cases in China.(2S,3S)-1,2-Epoxy-3-(Cbz-amino)-4-phenylbutane vendor The novel coronavirus has resulted in thousands of confirmed human infections in more than 20 countries, with more than 99 percent of cases in China.In April 2019, Glenmark had received approval from the Drugs Controller General of India (DCGI) for Remogliflozin Etabonate after successfully completing Phase-3 clinical trials.